Mild method for succinimide hydrolysis on ADCs: Impact on ADC potency, stability, exposure, and efficacy

Bioconjugate Chemistry

Volumn 25, Issue 10, 2014, Pages 1871-1880

  Tumey, L Nathan ^a   Charati, Manoj ^a   He, Tao ^a   Sousa, Eric ^a   Ma, Dangshe ^a   Han, Xiaogang ^a   Clark, Tracey ^a   Casavant, Jeff ^a   Loganzo, Frank ^a   Barletta, Frank ^a   Lucas, Judy ^a   Graziani, Edmund I ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STABILITY;

A-RINGS; IN-VITRO; MALEIMIDES; MICHAEL-TYPE REACTION; SIMPLE++; SUCCINIMIDE; THIOETHERS; VITRO STABILITY;

HYDROLYSIS;

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; DRUG ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MALEIMIDE; SUCCINIMIDE; SULFIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; IMMUNOTOXIN; SUCCINIMIDE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYDROLYSIS; DRUG POTENCY; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ANIMAL; BLOOD; CHEMISTRY; HYDROLYSIS; NEOPLASMS; PATHOLOGY; PROTEIN STABILITY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG STABILITY; HUMANS; HYDROLYSIS; IMMUNOTOXINS; MICE; NEOPLASMS; PROTEIN STABILITY; SUCCINIMIDES; SULFIDES;

EID: 84908052265     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc500357n     Document Type: Article

References (19)

1. Beck, A. and Reichert Janice, M. (2014) Antibody-drug conjugates: present and future mAbs 6 (1) 15-7
2. Sassoon, I. and Blanc, V. (2013) Antibody-drug conjugate (ADC) clinical pipeline: a review Methods Mol. Biol. 1045, 1-27
3. Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., and Borzilleri, R. M. (2014) Antibody-drug conjugates: current status and future directions Drug Discovery Today 19 (7) 869-881
4. Gualberto, A. (2012) Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies Expert Opin. Invest. Drugs 21 (2) 205-216
5. Ballantyne, A. and Dhillon, S. (2013) Trastuzumab emtansine: first global approval Drugs 73 (7) 755-765
6. Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., Mountain, A., Flowers, D. A., Bernstein, I., and Gemtuzumab Ozogamicin, A. (2002) Potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia Bioconjugate Chem. 13 (1) 47-58
7. Boghaert, E. R., Khandke, K. M., Sridharan, L., Dougher, M., DiJoseph, J. F., Kunz, A., Hamann, P. R., Moran, J., Chaudhary, I., and Damle, N. K. (2008) Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples Cancer Chemother. Pharmacol. 61 (6) 1027-1035
8. Xie, H., Audette, C., Hoffee, M., Lambert, J. M., and Blaettler, W. A. (2004) Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice J. Pharmacol. Exp. Ther. 308 (3) 1073-1082
9. Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., and Senter, P. D. (2008) Contribution of linker stability to the activities of anticancer immunoconjugates Bioconjugate Chem. 19 (3) 759-765
10. Baldwin, A. D. and Kiick, K. L. (2011) Tunable degradation of maleimide-thiol adducts in reducing environments Bioconjugate Chem. 22 (10) 1946-1953
11. Shen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S.-F., Mai, E., Li, D., Tibbitts, J., Baudys, J., Saad, O. M., Scales, S. J., McDonald, P. J., Hass, P. E., Eigenbrot, C., Nguyen, T., Solis, W. A., Fuji, R. N., Flagella, K. M., Patel, D., Spencer, S. D., Khawli, L. A., Ebens, A., Wong, W. L., Vandlen, R., Kaur, S., Sliwkowski, M. X., Scheller, R. H., Polakis, P., and Junutula, J. R. (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 30 (2) 184-189
12. Stefano James, E., Busch, M., Hou, L., Park, A., and Gianolio Diego, A. (2013) Micro- and mid-scale maleimide-based conjugation of cytotoxic drugs to antibody hinge region thiols for tumor targeting Methods Mol. Biol. 1045, 145-71
13. Doroski, M. D., Maderna, A., O'Donnell, C. J., Subramanyam, C., Vetelino, B. C., Dushin, R. G., Strop, P., and Graziani, E. I. (Pfizer) Cytotoxic peptides and antibody drug conjugates thereof. Pat. Appl. No. WO 2013/072813 A2, reference document 20121107, May 23, 2013.
14. Sanderson, R. J., Hering, M. A., James, S. F., Sun, M. M. C., Doronina, S. O., Siadak, A. W., Senter, P. D., and Wahl, A. F. (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate Clin. Cancer Res. 11, 843-852
15. Jackson, D., Atkinson, J., Guevara, C. I., Zhang, C., Kery, V., Moon, S.-J., Virata, C., Yang, P., Lowe, C., Pinkstaff, J., Cho, H., Knudsen, N., Manibusan, A., Tian, F., Sun, Y., Lu, Y., Sellers, A., Jia, X.-C., Joseph, I., Anand, B., Morrison, K., Pereira, D. S., and Stover, D. (2014) In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates PLoS One 9 (1) e83865/1-e83865/14 14 pp.
16. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., Meyer, D. L., and Francisco, J. A. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10 (20) 7063-7070
17. Toda, N., Asano, S., and Barbas, C. F., III (2013) Rapid, stable, chemoselective labeling of thiols with Julia-Kocienski-like reagents: A serum-stable alternative to maleimide-based protein conjugation Angew. Chem., Int. Ed. 52 (48) 12592-12596
18. Badescu, G., Bryant, P., Swierkosz, J., Khayrzad, F., Pawlisz, E., Farys, M., Cong, Y., Muroni, M., Rumpf, N., Brocchini, S., and Godwin, A. (2014) A new reagent for stable thiol-specific conjugation Bioconjugate Chem. 25 (3) 460-469
19. Lyon, R., Setter, J., Bovee, T., Doronina, S., Hunter, J., Anderson, M., Balasubramanian, C., Duhino, S., Lieske, C., Li, F., and Senter, P. Self-stabilizing maleimides improve the stabilty and pharmacological properties of antibody-drug-conjugates. Nat. Biotechnol. 2014, in press